Alkermes Plc (ALKS)
Healthcare
Drug Manufacturers - Specialty & Generic
49.50 $
+1.1%
vs. previous close
Closing price · As of: 3. Aug 2026
Alkermes Plc (ALKS) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 4,393 million $. Tick rows to compare them in a chart.
| Tick rows to compare them in a chart (up to 4) | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2,279 | 2,136 | 2,124 | 2,207 | 2,155 | 2,056 | 2,082 | 2,253 | 2,330 | 2,530 | 4,258 | 4,393 | |
| 1,465 | 1,486 | 1,469 | 1,542 | 1,564 | 1,415 | 1,479 | 1,635 | 1,742 | 1,929 | 1,359 | 1,523 | |
| 648 | 457 | 421 | 535 | 396 | 291 | 400 | 521 | 616 | 1,120 | 352 | 512 | |
| 889 | 773 | 745 | 876 | 909 | 752 | 884 | 1,016 | 1,111 | 1,319 | 512 | 657 | |
| 340 | 333 | 317 | 370 | 370 | 390 | 322 | 355 | 355 | 334 | 408 | 456 | |
| 192 | 186 | 198 | 195 | 191 | 183 | 183 | 192 | 191 | 197 | 337 | 299 | |
| 431 | – | – | – | – | – | – | – | – | – | – | – | |
| 93 | 83 | 83 | 83 | 83 | 83 | – | – | – | 84 | 596 | 594 | |
| 11 | 2.0 | 0.9 | 0.9 | 0.9 | 0.9 | 84 | 84 | 84 | 84 | 1,784 | 1,761 | |
| 924 | 934 | 869 | 923 | 863 | 591 | 570 | 628 | 596 | 711 | 2,507 | 2,585 | |
| 503 | 520 | 459 | 516 | 454 | 465 | 444 | 506 | 474 | 543 | 599 | 662 | |
| 18 | 8.7 | 8.9 | 9.0 | 9.2 | 6.2 | 6.3 | 6.5 | 6.6 | 6.7 | 34 | 34 | |
| 87 | 66 | 77 | 105 | 37 | 46 | 60 | 99 | 68 | 108 | 102 | 332 | |
| 288 | 288 | 287 | 286 | 286 | – | – | – | – | – | 1,484 | – | |
| 1,356 | 1,203 | 1,255 | 1,284 | 1,292 | 1,465 | 1,512 | 1,625 | 1,733 | 1,819 | 1,752 | 1,809 | |
| -1,456 | -1,344 | -1,307 | -1,215 | -1,123 | -976 | -954 | -867 | -784 | -735 | -801 | -801 | |
| 172 | 170 | 173 | 171 | 167 | 167 | 169 | 168 | 169 | 169 | 166 | 167 |
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.